Subcutaneous tumor experiments based on the Osimertinib-resistant HCC827-TS cell line revealed that the HSP90 inhibitor AUY922 demonstrated considerable efficacy against Osimertinib-resistant EGFR-mutant LUAD, with IFI6 knockdown showing even greater therapeutic potential in vivo (Fig. 8G, H and Supplementary Fig. 4F). Here, HSP90AA1 is linked to neoplasm.